[Form 4] BioLife Solutions Inc. Insider Trading Activity

Rhea-AI Filing Summary

BioLife Solutions Inc. (BLFS) Form 4 filing: Chief Marketing Officer Todd Berard sold 304 common shares of BLFS on 07/07/2025 at $22.27 per share. The disposition was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted 01/03/2023 to cover tax-withholding obligations linked to restricted-stock vesting.

Following the transaction, Berard still beneficially owns 134,618 shares, maintaining a sizable equity stake. No derivative transactions were reported. The small size (≈0.2% of his reported holdings) and the use of a 10b5-1 plan limit the strategic signal of the sale, suggesting a routine administrative move rather than a shift in insider sentiment.

Positive

• Insider retains 134,618 shares, indicating continued alignment with shareholder interests.
• Transaction executed under a Rule 10b5-1 plan, reducing concerns about opportunistic selling.

Negative

• Any insider sale may be perceived negatively, even if small.
• The filing provides no offsetting insider purchases to signal confidence.

Insights

Financial Analyst

TL;DR – Minor 10b5-1 sale; signals neutral, low impact.

The CMO’s sale of 304 shares for ~$6.8k is immaterial relative to his 134.6k-share position. Because the trade was executed under a pre-established Rule 10b5-1 plan for tax withholding, it does not necessarily reflect discretionary timing or negative sentiment. From a portfolio standpoint, the filing is not impactful; insider ownership remains high, and no derivative activity suggests hedging or leverage changes. I view the disclosure as routine, with negligible influence on valuation or liquidity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2025		S(1)		304	D	$22.27	134,618	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	07/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BLFS shares did the CMO sell?

Todd Berard disposed of 304 common shares.

At what price were the BioLife Solutions shares sold?

The shares were sold at $22.27 per share.

When did the insider sale occur?

The transaction date was July 7, 2025.

Why was the sale made under a Rule 10b5-1 plan?

The plan was adopted to cover tax-withholding obligations from restricted-stock vesting, indicating a pre-scheduled administrative purpose.

How many BLFS shares does the CMO own after the sale?

Todd Berard beneficially owns 134,618 shares following the transaction.

Does this Form 4 indicate any options or derivatives activity?

No derivative securities were reported in the filing.